Clinical trials: Atezolizumab
Breast Cancer
Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer
PROMETEO is a window opportunity, single arm, exploratory study to evaluate the effect of T- VEC combined with Atezolizumab in women with operable early breast cancer who present residual disease after Neoadjuvant Chemotherapy…
- Trial name
- PROMETEO (NCT03802604)
- Testing
- Talimogene laherparepvec, Atezolizumab
- Where
- 4 sites in Spain
- Volunteers
- 28 people
- Sponsor
- SOLTI Breast Cancer Research Group
Ovarian Neoplasms
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in…
- Trial name
- NCT02659384
- Testing
- Bevacizumab, atezolizumab, acetylsalicylic acid
- Where
- 12 sites in France, Netherlands and 3 more
- Volunteers
- 122 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
The hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment.
- Trial name
- COMET (NCT06908993)
- Testing
- Tepotinib, Pemetrexed (Alimta), Vinorelbine
- Where
- 29 sites in France
- Volunteers
- 133 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments.
- Conditions
- Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder, Squamous Cell Carcinoma of the Urinary Tract
- Trial name
- NCT06161532
- Testing
- Sacituzumab govitecan, Atezolizumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Solid Cancers
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic…
- Trial name
- NCT02323191
- Testing
- Atezolizumab, Emactuzumab
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 221 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC)
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
The goal of this clinical trial is to compare the safety and efficacy of sequential Transarterial Chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) versus Y90-radioembolisation (SIRT), followed by systemic…
- Trial name
- BIIRTH (NCT07293468)
- Testing
- Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- Tuen Mun Hospital
Neuroendocrine Tumor, Anaplastic Thyroid Cancer
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system.
- Conditions
- Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma
- Trial name
- CABATEN (NCT04400474)
- Testing
- Cabozantinib 40 mg
- Where
- 15 sites in Spain
- Volunteers
- 93 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Squamous Cell Carcinoma of the Anal Canal
Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
The peculiarity of anal cancers, with well-established radical chemoradiotherapy that allows tumor-neoantigen formation with platinum-based chemotherapy and radiotherapy with radio-sensitizing chemotherapy could create the…
- Trial name
- TIRANUS (NCT05661188)
- Testing
- Atezolizumab plus Tiraglolumab
- Where
- 13 sites in Spain
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Unresectable Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including…
- Trial name
- ISMIO001 (NCT07204327)
- Testing
- Atezo+Bev plus Locoregional Therapy
- Where
- China
- Volunteers
- 1,136 people
- Sponsor
- Zhongda Hospital
Pancreatic Neoplasms, Pancreatic Cancer
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Background: Stereotactic body radiation therapy (SBRT) is used to treat cancer. It is a way of giving very focused beams of radiation to tumors.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas
- Trial name
- NCT02311361
- Testing
- Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Metastatic Cancer
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
The aim of this study is to assess the effectiveness of a battery of autoantibodies to predict the occurrence of immune-related adverse events (irAEs) in patients with cancer who will be treated with immune checkpoint inhibitors…
- Conditions
- Cancer, Metastatic Cancer, Solid Organ Cancer
- Trial name
- AUTENTIC (NCT03868046)
- Testing
- Treatment with immune checkpoint inhibitors., Blood tests.
- Where
- Spain
- Volunteers
- 242 people
- Sponsor
- Hospital Universitario Araba
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
This phase II trial tests how well atezolizumab works in combination with tiragolumab in treating patients with rare solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts…
- Conditions
- Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
- Trial name
- NCT05715281
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
This is a single-arm, single-site pilot of Radium-223 (55 kBq/kg) IV q3 weeks for up to 6 doses in combination with Atezolizumab 1200mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity…
- Trial name
- NCT03208712
- Testing
- Atezolizumab, Radium-223
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Breast Cancer
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy)…
- Trial name
- INDUCE (NCT06793553)
- Testing
- Induction therapy
- Where
- Japan
- Volunteers
- 106 people
- Sponsor
- Japan Breast Cancer Research Group
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
This phase I/II trial studies the side effects and how well bintrafusp alfa and stereotactic body radiation therapy work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has occurred…
- Trial name
- NCT04220775
- Testing
- Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Muscle-invasive Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are…
- Trial name
- IMvigor011 (NCT04660344)
- Testing
- Atezolizumab, Signatera
- Where
- 141 sites in United States, Argentina and 21 more
- Volunteers
- 761 people
- Sponsor
- Hoffmann-La Roche
HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.
- Trial name
- NCT03430518
- Testing
- Durvalumab, Eribulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Amy Tiersten
Solid Tumors
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
This is a study to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab in participants with advanced solid tumors including the following cohorts: squamous cell carcinoma of the head and neck…
- Trial name
- NCT03264066
- Testing
- Cobimetinib, Atezolizumab, Atezolizumab Cohort 7
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche